AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00586482
Drug: Placebo Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
Trial: NCT00886236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
Trial: NCT00384176
Drug: Leucovorin (in FOLFOX)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous infusion
Trial: NCT04439773
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the control group will be given the same volume of saline.
Trial: NCT00379990
Drug: GW274150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg /day
Trial: NCT00379990
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7.5 mg/day
Trial: NCT03852459
Drug: S-Ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel 5%
Trial: NCT03852459
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Gel
Trial: NCT03380533
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adhesive patch with the same macroscopic characteristics to the buprenorphine patch, without drugs.
Trial: NCT03380533
Drug: Multimodal Oral Scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 75mg c 12h Tramadol 50mg c 12h. Rescues with tramadol 50 mg (maximum rescue dose 150mg, minimum frequency between rescues 4hs)
Trial: NCT01329731
Drug: elmex® gelée
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
Trial: NCT03380533
Drug: Placebo Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet that the patient consumes every 8 hours during the first five days
Trial: NCT00920088
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50mg
Trial: NCT00920088
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNRTI under investigation
Trial: NCT03881345
Drug: Anticoagulants
RxNorm normalized name: ANTICOAGULANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anticoagulation according to the main diagnosis
Trial: NCT01922089
Drug: LCZ696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 50 mg/100 mg/200 mg bid
Trial: NCT02113176
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01072266
Drug: INCB028060
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
Trial: NCT01817465
Drug: Motilitone ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01817465
Drug: Pantoline®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01817465
Drug: Motilitone® and Pantoline®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00430950
Drug: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
Trial: NCT00430950
Drug: olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
Trial: NCT04225728
Drug: Iron Sucrose IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will consisted of the administration for the IV route.~-The IV route in two doses will be diluted bolus injection of iron or normal saline at day 0 and day 14.
Trial: NCT04225728
Drug: Ferric polymaltose hydroxide complex IM
RxNorm normalized name: ferric hydroxide
DrugBank: Ferric hydroxide (DB13423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention will consisted of the administration for the IM route. Drug will be given in two series of injection; the first series will began at day 0 and consist of administration of 300 mg of iron per day in intramuscular injection up to the half of the total dose and the second series will began at day 14 for the administration of the other half with the same scheme than the first.
Trial: NCT00005586
Drug: L-leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005586
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00613834
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Trial: NCT00717184
Drug: Interleukin, NK cells
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02030314
Drug: Chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment of resistant hypertension in kidney transplant patients
Trial: NCT00821366
Drug: ARV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
Trial: NCT03096275
Drug: CYC
RxNorm normalized name: Cycrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
Trial: NCT03096275
Drug: Glucocorticoids
RxNorm normalized name: GLUCOCORTICOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
Trial: NCT03676751
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax® for oral suspension is supplied in bottles containing azithromycin dehydrate powder equivalent to 1200mg per bottle and the following inactive ingredients: sucrose; tribasic anhydrous sodium phosphate; hydroxypropyl cellulose; xanthan gum; FD\&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla, and banana. After constitution, a 5mL suspension contains 200mg of azithromycin.
Trial: NCT03676751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension of placebo for azithromycin
Trial: NCT03173053
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03173053
Drug: Clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT03173053
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01690221
Drug: VEN 307
RxNorm normalized name: Apis mellifera ven protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEN307 applied three times a day, in and around the anus, for 28 days.
Trial: NCT01690221
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied three times a day, in and around the anus, for 28 days.
Trial: NCT03801538
Drug: Nucleoside Analog (Substance)
RxNorm normalized name: Nucleoside analog (substance)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients do not need to change their NAs treatment.
Trial: NCT00398931
Drug: Comparator : placebo (unspecified) /Duration of Treatment : 5 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03330782
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)
Trial: NCT03330782
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in adult patients (20-60 years)
Trial: NCT03357055
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will receive an intravenous (IV) infusion of 10 ml of normal saline in a 10 ml syringe over 10 minutes starting 10 minutes before pneumatic tourniquet inflation. Throughout the procedure, patients will receive 10ml/hour normal saline infusion until the end of operation
Trial: NCT01400620
Drug: IZN-6N4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
Trial: NCT03918590
Drug: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID
Trial: NCT03918590
Drug: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: preservative-free Artificial Tears
Trial: NCT00492765
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage and frequency as per Biogen Idec protocol
Trial: NCT00492765
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage and frequency the same as simvastatin as per Biogen Idec Protocol
Trial: NCT02326025
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT02021370
Drug: BAY85-3934
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25mg Tablet
Trial: NCT02021370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet
Trial: NCT00741936
Drug: MaZiRenWan (MZRW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Trial: NCT03236740
Drug: Ethinyl Estradiol-cyprosterone acetate
RxNorm normalized name: cyproterone / ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
Trial: NCT00741936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Trial: NCT00109759
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00321737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
Trial: NCT02025751
Drug: Placebo Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
Trial: NCT01870245
Drug: ACHN-975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous multiple dose
Trial: NCT01870245
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous multiple dose
Trial: NCT03885882
Drug: E0302 SR1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0302 SR1, oral tablet.
Trial: NCT03885882
Drug: E0302 SR3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0302 SR3, oral tablet.
Trial: NCT03885882
Drug: E0302 SR2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0302 SR2, oral tablet.
Trial: NCT03885882
Drug: E0302 IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E0302 IR, oral tablet.
Trial: NCT03977974
Drug: LY3526318
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03977974
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04400760
Drug: DAPA Tx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention, dapagliflozin will be administered 10mg per oral daily for two weeks.
Trial: NCT04300829
Drug: cicaderma + simple hygiene rules
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicaderma ointment (2 applications / day: after the radiotherapy session) and in the evening) + simple hygiene rules
Trial: NCT02624726
Drug: 5 Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 Fluorouracil: 400mg/m2, bolus infusion in \<5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
Trial: NCT02624726
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
Trial: NCT03431974
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcrystalline filled capsule to mimic capsule containing aminopterin tablets
Trial: NCT02499315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
Trial: NCT00003972
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00588640
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
Trial: NCT00522444
Drug: Nebulized Magnesium Sulfate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3% solution of magnesium heptahydrate, which is equivalent to 3.18% anhydrous magnesium sulfate
Trial: NCT03655236
Drug: K0706
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose, orally, once-daily
Trial: NCT03655236
Drug: K0706
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high dose, orally, once-daily
Trial: NCT04219735
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline 100mg BID
Trial: NCT04219735
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03516084
Drug: ZL-2306(nirapairb)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Trial: NCT03516084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose is 300mg QD or 200mg QD based on baseline weight and platelet count.
Trial: NCT01859741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered IV
Trial: NCT02551575
Drug: Treatment of MTX and HCQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Trial: NCT01454622
Drug: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
Trial: NCT02551575
Drug: Integrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.~Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.~Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks.
Trial: NCT01454622
Drug: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
Trial: NCT01298401
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04232813
Drug: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
RxNorm normalized name: Estradiol 10 MCG Vaginal Tablet [VAGIFEM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To insert the tablets the patient must use the applicator provided in the way explained in the prospectus.
Trial: NCT02221037
Drug: GSK2862277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Trial: NCT02221037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device.
Trial: NCT04031612
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy
Trial: NCT01618591
Drug: Single dose azithromycin 500 mg
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Trial: NCT01618591
Drug: Single dose azithromycin 1000 mg plus loperamide
RxNorm normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Trial: NCT01618591
Drug: Single dose azithromycin 1000 mg plus placebo
RxNorm normalized name: azithromycin 1000 MG
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
Trial: NCT00391079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
Trial: NCT00635284
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nab-rapamycin
Trial: NCT00976092
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v. bolus of 70-100 IU/kg body weight
Trial: NCT01031966
Drug: Thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Trial: NCT01031966
Drug: Thymosin alpha 1
RxNorm normalized name: Thymosin alpha 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
Trial: NCT03832699
Drug: Endometrin 100Mg Vaginal Insert
RxNorm normalized name: Endometrin 100mg Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal Endometrin 100 mg twice daily
Trial: NCT00352144
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT00508625
Drug: AMG 951 (rhApo2L/TRAIL)
RxNorm normalized name: Mane 'N Tail Mineral Ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
Trial: NCT01816815
Drug: BAY1002670
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01816815
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02796131
Drug: RDX5791
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02796131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo